Sign In
Buy SYRE
$93.73
-4.01 (-4.10%)
At Close: Jul 13, 2026
Spyre Therapeutics Announces Grants of Inducement Awards
04:05pm, Thursday, 02'nd Jul 2026
WALTHAM, Mass., July 02, 2026 (GLOBE NEWSWIRE) -- Spyre Therapeutics, Inc. (NASDAQ: SYRE) (the “Company” or “Spyre”), a clinical-stage biotechnology company committed to developing next-genera
Spyre Therapeutics: Deep And Diverse Immunology Pipeline Awaiting Data
08:00am, Tuesday, 30'th Jun 2026
Spyre Therapeutics is building a long-acting antibody platform across IBD and rheumatology. However, they only have Phase 2 assets, with SPY001 and SPY002 that recently showed encouraging Part A data.
Is SYRE Stock a Buy Now or a Wait-and-See Biotech Story Today
12:25pm, Monday, 29'th Jun 2026
Spyre Therapeutics SYRE has given investors a classic biotech dilemma. The pipeline is advancing, the cash balance is large and the stock has already moved sharply higher.
Spyre Therapeutics Stock Outlook Hinges on 2026 Study Catalysts
12:21pm, Monday, 29'th Jun 2026
Spyre Therapeutics SYRE has become a closely watched clinical-stage biotech stock as investors look ahead to a busy stretch of data readouts that could define the company's next phase. The company i
SYRE and Spyre Ride New IBD Trends in Biotech Drug Design
12:21pm, Monday, 29'th Jun 2026
SYRE is targeting major IBD drug trends with long-acting antibodies and combination therapies, but its future still hinges on clinical trial results.
Spyre Therapeutics: A Platform Where The Combination Strategy Is The Real Asset
02:34pm, Friday, 26'th Jun 2026
Spyre is building a modular immunology platform targeting IBD and rheumatic diseases with internally developed, long-acting antibody combinations. Positive Phase 2 data for SPY001 and SPY002 in ulcera
Biotech ETF Index Surges 10% After Rebalance
11:31am, Thursday, 25'th Jun 2026
After a sweeping semi-annual rebalance, the biotech index underlying the ALPS Medical Breakthroughs ETF (SBIO) gained over 10% in just six trading days beginning June 18. Key Takeaways: SBIO's underly
Spyre says bowel disease drug cuts inflammation in mid-stage trial
08:28am, Monday, 15'th Jun 2026
Spyre Therapeutics said on Monday its experimental bowel disease drug met the main goal of significantly reducing disease severity in a mid-stage trial.
SPY002 met its primary endpoint with a statistically significant reduction of 10.7 points (p
Healthcare ETFs: From Broad Exposure to Big Breakthroughs
07:14am, Thursday, 11'th Jun 2026
With AI and space dominating many of the market's most popular investment themes, it can be difficult to find differentiated opportunities. Healthcare is often viewed as one of the more defensive sect
Spyre Therapeutics, Inc. (SYRE) Presents at Goldman Sachs 47th Annual Global Healthcare Conference 2026 Transcript
12:58pm, Monday, 08'th Jun 2026
Spyre Therapeutics, Inc. (SYRE) Presents at Goldman Sachs 47th Annual Global Healthcare Conference 2026 Transcript
Spyre Therapeutics Announces Grants of Inducement Awards
04:01pm, Friday, 05'th Jun 2026
WALTHAM, Mass., June 05, 2026 (GLOBE NEWSWIRE) -- Spyre Therapeutics, Inc. (NASDAQ: SYRE) (the “Company” or “Spyre”), a clinical-stage biotechnology company committed to developing next-genera
SYRE Completes Enrollment in SKYWAY Basket Study on SPY072, Stock Up
12:01pm, Thursday, 04'th Jun 2026
Spyre Therapeutics gains after completing enrollment in all SKYWAY phase II sub-studies evaluating SPY072 across three rheumatic diseases.
Spyre Therapeutics Announces Completion of Enrollment in SKYWAY Basket Trial Evaluating SPY072 (anti-TL1A) in RA, PsA, and axSpA
08:00am, Wednesday, 03'rd Jun 2026
Enrollment for psoriatic arthritis (PsA) and axial spondyloarthritis (axSpA) sub-studies of the SKYWAY basket trial are complete
Spyre Therapeutics to Participate in Upcoming June Investor Conferences
04:10pm, Tuesday, 26'th May 2026
WALTHAM, Mass., May 26, 2026 (GLOBE NEWSWIRE) -- Spyre Therapeutics, Inc. (NASDAQ: SYRE), a clinical-stage biotechnology company pioneering long-acting antibodies and antibody combinations to redefine
